Development and Validation of the Quantification of GML-1 Compound ( N -benzyl- N -methyl-1-phenylpyrrolo[1,2- A ] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

A. A. Novitskiy; P. O. Bochkov; A. A. Litvin; V. P. Zherdev; E. V. Blynskaya

doi:10.3103/S0027131418010042

Development and Validation of the Quantification of GML-1 Compound (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-A] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

Autores: Novitskiy A.A.¹, Bochkov P.O.¹, Litvin A.A.¹, Zherdev V.P.¹, Blynskaya E.V.¹
Afiliações:
1. Zakusov Institute of Pharmacology
Edição: Volume 72, Nº 6 (2017)
Páginas: 322-324
Seção: Article
URL: https://journals.rcsi.science/0027-1314/article/view/163557
DOI: https://doi.org/10.3103/S0027131418010042
ID: 163557

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

The technique of quantitative determination of a new compound, possessing anxiolytic activity, GML-1 in the blood plasma of rats is developed and validated. The analysis is performed by HPLC–MS. The method is linear in the range of 50–1000 ng/mL. 83.63% of GML-1 was recovered. The detection limit was 25 ng/mL.